Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 10/20 | 0.38 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25260581 | 0.90 | MGLL (0.38) | MGLL | |
| SCHEMBL29497046 | 0.84 | PTPRZ1 (0.37) | MGLLPTPRZ1SCN3ATEAD1CHRM1 | |
| SCHEMBL25251927 | 0.84 | LMNA (0.33) | MGLLKCNH2 | |
| SCHEMBL25258066 | 0.79 | TEAD1 (0.35) | MGLLTEAD1 | |
| SCHEMBL25295986 | 0.77 | TEAD1 (0.38) | TEAD1 | |
| SCHEMBL25254799 | 0.76 | MGLL (0.46) | MGLLKCNH2CACNA1CSCN5A | |
| SCHEMBL25297074 | 0.76 | MGLL (0.46) | MGLLKCNH2CACNA1CSCN5A | |
| SCHEMBL25290096 | 0.76 | MGLL (0.46) | MGLLKCNH2CACNA1CSCN5A | |
| SCHEMBL25291484 | 0.76 | PTPRZ1 (0.49) | MGLLPTPRZ1SCN3ATEAD1MMP2 | |
| SCHEMBL29496964 | 0.74 | MGLL (0.33) | MGLLSCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | claimed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | claimed |
| CN-115989228-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | claimed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | claimed |
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| CN-115989228-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | CBR3, BRIX1, CCNY | MGLL 996/4885PTPRZ1 3242/4885SCN3A 3699/4885 |
| US-11981661-B2 | Heterocyclic compounds | CBR3, BRIX1, CCNY | MGLL 996/4885PTPRZ1 3242/4885SCN3A 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.